Retreatment or prolonged antiviral therapy in severe acute respiratory syndrome Coronavirus-2 infection among immunocompromised patients during 2022–2023: A nationwide claims-based cohort study in Japan
Yamamoto S., Ikeuchi K., Saito M., Okushin K., Kado A., Kitaura S., Okugawa S., Tsutsumi T.